Preoperative planning of arterial chemoembolization with drug-saturated microspheres for women with recurrent pelvic tumors complicated by bleeding

Arterial chemoembolization is an X-ray surgical method that is used for recurrent pelvic tumors complicated by bleeding. It combines occlusion of tumor vessels and local chemotherapy, for which a cytostatic and drug-saturated microspheres are used. To obtain a result, two conditions must be met: carefully close all tumor afferents, treat the maximum tumor volume with saturated microspheres.

The aim of the work: to define the key points of preoperative planning for recurrent pelvic tumors in women in order to achieve reliable hemostasis and cytoreduction.

An analysis of 17 women with recurrent tumors complicated by tumor bleeding is presented. The first group consisted of 7 patients in whom the uterus was not removed, the second group consisted of 10 patients with removed uterus. For preoperative planning, magnetic resonance imaging of pelvis and selective angiography of the branches of the anterior and posterior trunk of the internal iliac artery were used. The sources of blood supply to the tumor were different and depended on the localization of the process in the upper, middle, and lower levels of pelvis. Multidisciplinary planning made it possible to achieve reliable hemostasis in all cases, to prevent complications from the pelvic organs.

1. Tianrong S., Wei W., Ping L., Chunlin Ch. Pharmacokinetic comparison between pelvic transarterial chemoembolization and transcatheter arterial chemotherapy in an animal model. Mol Med Rep 2009:663-7. DOI: 10.3892/mmr_00000154.

2. Pfaendler K.S., Tewari K.S. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 2016;214(1):22-30. DOI: 10.1016/j.ajog.2015.07.022.

3. Murakata A.L., Lewin-Smith M.R., Specht Ch.S. et al. Characterization of acrylic polyamide plastic embolization particles in vitro and in human tissue sections by light microscopy, infrared microspectroscopy and scanning electron microscopy with energy dispersive X-ray analysis. Modern Pathol 2006;19:922-30.

4. Pfaendler K.S., Tewari K.S. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 2016;214(1):22-30. DOI: 10.1016/j.ajog.2015.07.022.

5. Kennoki N., Saguchi T., Sano T. et al. Long-term histopathologic follow-up of a spherical embolic agent; observation of the transvascular migration of HepaSphereTM. BJR Case Rep 2019;5(1):20180066. DOI: 10.1259/bjrcr.20180066.

6. De Baere T., Plotkin S., Yu R. et al. An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin. J Vasc Interv Radiol 2016;27(9):1425-31. DOI: 10.1016/j.jvir.2016.05.015.

7. Hiraki T., Koizumi J., Arai Y. et al. Transcatheter arterial embolization of hypervascular tumors with HepaSphere: prospective multicenter open label clinical trial of microspheres in Japan. Jpn J Radiol 2015;33(8):479-86. DOI: 10.1007/s11604-015-0448-8.

8. Xuegang Y., Guohui X., Ge W. et al. Superselective uterine artery chemoembolization for treatment of locally advanced cervical cancer. Chinese J Radiol 2013;47(8):735-8.

9. Instruction for loading cytostatic agents into the HepaSphere microspheres. (In Russ.).

10. Bi Y., Wang Y., Zhang J., Shi X. Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer. Abdominal Radiol (New York) 2021. DOI: 10.1007/s00261-021-03267-6.

11. Wang H.X., Li S.H., Zhao H.Y. Effect of different preoperative neoadjuvant chemotherapy on cervical cancer angiogenesis and cell proliferation. J Hainan Med University 2016;22(20):115-8.

12. Tinelli A., Prudenzano R., Malvasi A. et al. Emergency endovascular nanopharmacologic treatment in advanced gynecological cancers. Int J Gynecol Cancer 2010;20:1250-5.

13. Kedrova A.G., Lebedev D.P., Shablovskiy O.R. et al. Chemoembolization of pelvic vessels as a stage of treatment for cervical and uterine cancer. Klinicheskaya praktika = Clinical practice 2016;(2):50-6. (In Russ.).

14. Balcacer P., Shergill A., Litkouhi B. MRI of cervical cancer with a surgical perspective: staging, prognostic implications and pitfalls. Abdominal Radiol 2019;44:2557-71. DOI: 10.1007/s00261-019-01984-7.

15. Lee S.I., Atri M. 2018 FIGO Staging System for Uterine Cervical Cancer: Enter Cross-sectional Imaging. Radiology 2019;292(1):15-24. DOI: 10.1148/radiol.2019190088.

16. Yin Y.J., Li H.Q., Sheng X.G. et al. The treatment of pelvic locoregional recurrence of cervical cancer after radical surgery with intensity-modulated radiation therapy compared with conventional radiotherapy: a retrospective study. Int J Gynecol Cancer 2015;25(6):1058-65.

17. Merz J., Bossart M., Bamberg F., Eisenblaetter M. FIGO staging for cervical cancer - a new role for MRI. Rofo 2020;192(10):937-44. DOI: 10.1055/a-1198-5729.

18. De Foucher T., Bendifallah S., Ouldamer L. et al. Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicenter study from the FRANCOGYN group. Eur J Surg Oncol 2019;45(4):659-65. DOI: 10.1016/j.ejso.2018.11.014.

19. Bandyopadhyay A., Mukherjee U., Ghosh S. et al. Pattern of failure with locally advanced cervical cancer -a retrospective audit and analysis of contributory factors. Asian Pac J Cancer Prev 2018;19(1):73-9. DOI: 10.22034/APJCP.2018.19.1.73.

20. Song J., Chen W., Zhu X. et al. Shortterm efficacy, safety, and cost-effectiveness of transarterial chemoembolization with drug-eluting beads versus synchronous radiochemotherapy for cervical cancer. Ginecol Obstet 2019;147(1):29-35. DOI: 10.1002/ijgo.12888.